HUTCHMED (China) Limited
NASDAQ:HCMDrug Manufacturers - Specialty & Generic
+$0.16 today
- Market cap
- $2.44B
- Beta
- 0.37
- P/E (TTM)
- 46.2
- EPS (TTM)
- $0.05
Volume 0.04M
Average 0.04M
HCM Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
HUTCHMED (China) LimitedNASDAQ: HCM
Total Equity · Q4 FY2025 · quarter ended Dec 2025
Total equity rises 62.1% from a year ago
Total equity stood at $1.25B at the end of Q4 FY2025, up 62.1% from a year earlier. Over 3 fiscal years it compounded at +25.2% a year.
Context
- Total equity amounted to 71.4% of total assets at the end of Q4 FY2025, up 10.8 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +62.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 1.25B USD
- Year-over-year change
- +62.1%
- 4-year CAGR
- +4.7%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.25B | +62.1% |
| FY2024 | 2024-12-31 | 771.85M | +3.8% |
| FY2023 | 2023-12-31 | 743.39M | +16.7% |
| FY2022 | 2022-12-31 | 636.87M | -38.7% |
| FY2021 | 2021-12-31 | 1.04B | — |
Total Equity vs competitors
How HCM compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +62.1% is the 2nd highest of 11, against a peer median of -6.3%.
- Total equity amounts to 71.4% of total assets for HCM, versus a peer median of 65.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | €17.75B EUR | -4.1% | -1.4% | 87.3% | |
| Jun 2026 | $6.34B USD | +52.1% | +5.7% | 80.6% | |
| Jun 2026 | $5.96B USD | +12.4% | -40.2% | 47.6% | |
| Jul 2026 | $1.84B USD | -9.3% | -4.6% | 73.9% | |
AAPGAscentage Pharma Group International | Dec 2025 | CN¥1.34B CNY | +387.0% | +48.4% | 33.7% |
| Sep 2026 | $1.27B USD | +25.9% | +10.4% | 75.7% | |
| Dec 2025 | $1.25B USD | +62.1% | +25.2% | 71.4% | |
| Mar 2026 | $937.27M USD | -8.5% | +43.0% | 91.0% | |
| Jun 2026 | $607.04M USD | -23.3% | -11.9% | 56.5% | |
| Jun 2026 | $464M USD | -15.5% | -1.3% | 50.2% | |
| Dec 2025 | -$8.32M USD | -132.7% | — | 24.2% | |
| Peer median (excluding HCM) | — | -6.3% | -1.3% | 65.2% | |
Competitors are the stored peer set for HCM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 377.54M | 313.28M | 283.59M | 153.96M | 71.33M |
| Short-term Investments | 634.16M | 317.72M | 602.75M | 682.15M | 1.3B |
| Net Receivables | 147.73M | 126.72M | 150.46M | 167.74M | 147.83M |
| Inventory | 35.76M | 56.69M | 50.26M | 50.4M | 41.13M |
| Other Current Assets | 2.76M | 3.15M | 2.68M | 3.3M | 2.77M |
| Total Current Assets | 1.21B | 839.89M | 1.1B | 1.07B | 1.57B |
| Property, Plant & Equipment (Net) | 66.32M | 84.67M | 104.39M | 97M | 97.65M |
| Goodwill | 3.38M | 3.14M | 3.06M | 2.99M | 3.11M |
| Intangible Assets | 163K | 3.22M | 21K | 0 | 8.94M |
| Long-term Investments | (557.68M) | (243.94M) | 48.41M | (599.39M) | 52.25M |
| Tax Assets | 9.4M | 15.37M | 15.46M | 0 | 12.66M |
| Other Non-current Assets | 639M | 327.1M | 11.59M | 707.04M | 11.15M |
| Total Non-current Assets | 160.59M | 189.56M | 182.93M | 207.64M | 185.76M |
| Total Assets | 1.37B | 1.03B | 1.28B | 1.27B | 1.75B |
| Account Payables | 41.18M | 71.12M | 36.33M | 42.52M | 45.53M |
| Short-term Debt | 26.91M | 3.71M | 31.16M | 23.37M | 27.85M |
| Tax Payables | 15.55M | 1.11M | 2.58M | 1.55M | 0 |
| Deferred Revenue | 15.55M | 13.35M | 57.64M | 0 | 31.42M |
| Other Current Liabilities | 40.95M | 37.39M | 228.93M | 290.08M | 176.94M |
| Total Current Liabilities | 311.66M | 353.9M | 403.03M | 376.56M | 315.78M |
| Long-term Debt | 0 | 18.1M | 48.19M | 59.43M | 68.19M |
| Deferred Tax Liabilities | 2.77M | 2.71M | 1.48M | 2.99M | 255K |
| Deferred Revenue (Non-current) | (2.77M) | 190K | 69.48M | 48.43M | 20.13M |
| Other Non-current Liabilities | 14.33M | 12.47M | 11.35M | 10.84M | 95.63M |
| Total Non-current Liabilities | 21.49M | 38.67M | 133.36M | 125.78M | 186.06M |
| Total Liabilities | 333.15M | 392.58M | 536.39M | 502.34M | 501.84M |
| Common Stock | 86.45M | 86.48M | 87.13M | 87.16M | 87.23M |
| Retained Earnings | (610.33M) | (971.48M) | (870.87M) | (833.17M) | (378.64M) |
| Accumulated OCI | 5.57M | (1.9M) | (8.16M) | (11.59M) | (4.53M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 52.62M | 26.5M | 12.85M | 11.92M | 13.34M |
| Total Equity | 1.04B | 636.87M | 743.39M | 771.85M | 1.25B |
| Total Debt | 38.98M | 27.01M | 86.13M | 89.82M | 97.89M |
| Net Debt | (338.56M) | (286.27M) | (197.46M) | (64.14M) | 26.56M |
HUTCHMED (China) Limited
NASDAQ:HCM
Intrinsic Alpha fair value
Locked
Current Price
$13.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.